Exogenous NAD, nicotinamide mononucleotide, or nicotinamide riboside is required for the growth of Haemophilus influenzae. These compounds have been defined as the V-factor growth requirement. We have previously shown that the internalization of nicotinamide riboside is energy dependent and carrier mediated with saturation kinetics. Thionicotinamide riboside, 3-pyridinealdehyde riboside, 3-acetylpyridine riboside, and 3-aminopyridine riboside were prepared from their corresponding NAD analogs. These compounds and several other nicotinamide riboside analogs were evaluated for their ability to support the growth of H. influenzae and for their ability to block the uptake of [carbonyl-'4C] Early studies regarding Haemophilus species determined that Haemophilus parainfluenzae requires NAD (V factor) for growth (21-23). Similar studies with Haemophilus influenzae found that both NAD and hemin (X factor) are required for growth (7, 8) . The inability of H. influenzae to grow in the presence of quinolinic acid or nicotinic acid indicated the lack of a de novo biosynthetic pathway or a Preiss-Handler pathway (11). The inability of nicotinamide (Nam) to serve as a V factor indicated that H. influenzae was also incapable of synthesizing NAD through any of the previously investigated pyridine nucleotide cycles (10, 14).
Early studies regarding Haemophilus species determined that Haemophilus parainfluenzae requires NAD (V factor) for growth (21) (22) (23) . Similar studies with Haemophilus influenzae found that both NAD and hemin (X factor) are required for growth (7, 8) . The inability of H. influenzae to grow in the presence of quinolinic acid or nicotinic acid indicated the lack of a de novo biosynthetic pathway or a Preiss-Handler pathway (11) . The inability of nicotinamide (Nam) to serve as a V factor indicated that H. influenzae was also incapable of synthesizing NAD through any of the previously investigated pyridine nucleotide cycles (10, 14) .
The ability of nicqtinamide riboside (NR) and nicotinamide mononucleotide (NMN) to support the growth of H. influenzae suggested the existence of a synthetic NAD pathway in which NMN or NR is used as a precursor (3, 12, 21, 25) .
Subsequent studies with H. influenzae determined that NAD is initially cleaved to NMN and AMP by a periplasmic nucleotide pyrophosphatase (15) . NMN is then dephosphorylated to NR and internalized (5) . Inside the cell, NR is either metabolized to NAD or is degraded to Nam and ribose-5-phosphate. Intracellularly produced NAD can be degraded to Nam and ADP-ribose by an NAD glycohydrolase, as shown in Fig. 1 (3) . The 10 ,uM in BHI broth (37 g of BHI per liter of distilled H20). Viable cell counts were determined by dilution on chocolate agar plates by using 0.9% NaCl with 0.05% Tween 80 for dilutions.
Chemicals and reagents. NAD, NADH, NADP, NMN, nicotinic acid adenine dinucleotide (NAAD), nicotinamide hypoxanthine dinucleotide (NHD), nicotinamide guanine dinucleotide (NGD), nicotinamide 1,N6-ethenoadenine dinucleotide (NED), Nam, 3-aminopyridine adenine dinucleotide (3-AmPAD), 3-acetylpyridine adenine dinucleotide (3-AcPAD), thionicotinamide adenine dinucleotide (Thio NAD),2,4-dinitrophenol (DNP), hematin, and ATP were obtained from Sigma Chemical Co. (St. Louis, Mo.). 5-(P-D- 3 -aminopyridine riboside (3-AmPR), 3-acetylpyridine riboside (3-AcPR), thionicotinamide riboside (ThioNR), and 3-pyridinealdehyde riboside (3-PAR) were prepared through a two-step enzymatic degradation process starting with the respective dinucleotide compound. The dinucleotide was dissolved in 50 mM Tris hydrochloride buffer (pH 7.4, 37°C) that was supplemented with 10 mM MgC12 to a final concentration of 1 mg/ml and was then treated with a snake venom nucleotide pyrophosphatase isolated from Crotalus atrox venom (Sigma) (17, 19) . The nucleotide pyrophosphatase was added at a concentration of 0.7 mg/ml. Incubation at 37°C for 8 h resulted in almost complete conversion of the dinucleotide compounds to the respective mononucleotides, as indicated by thin-layer chromatography (TLC), which was performed as described below.
The mononucleotide reaction mixture was adjusted to pH 4.5 with concentrated HCI. Prostatic acid phosphatase (Calbiochem-Behring, La Jolla, Calif.) was added to a final concentration of 0.1 mg/ml. Incubation for 12 h resulted in almost complete dephosphorylation of each mononucleotide, as indicated by TLC (18) . Approximately 1 ml of the nucleoside mixture, at a concentration of 1 mg/ml, was then loaded onto a column (1 by 10 cm) packed with Dowex 1-X8, 200-400 mesh anionexchange resin in the chloride form (4, 19) . The column was eluted with deionized H20 by gravity, and 1-ml fractions were collected over 20 min. The pyridine ribosides were found in fractions 4 through 7 and adenosine was eluted in fractions 11 through 16, as determined by TLC. Trace amounts of the dinucleotide, mononucleotide, and AMP were also separated from the pyridine ribosides during this procedure. Purity and structural conformation was confirmed through high-performance liquid chromatographic (HPLC) analysis and proton nuclear magnetic resonance ('H NMR).
TLC. TLC was performed on Baker-flex Cellulose F (J. T. Baker Chemical Co., Phillipsburg, N.J.) or 13254 Cellulose (Eastman Kodak Co., Rochester, N.Y.) by using a solvent system consisting of 70% ethanol and 30% 1 M ammonium acetate adjusted to pH 5.0 with concentrated HCl (19) . This system was found to separate readily the dinucleotide, mononucleotide, pyridine riboside, and the corresponding pyridine compounds of each NAD analog described above. The Rf values for the nicotinamide and adenine compounds were as follows: NAD, 0.12; NMN, 0.31; NR, 0.62; Nam, 0.84; AMP, 0.24; adenosine, 0.62; and adenine, 0.57. This system was used to follow dinucleotide metabolism and degradation.
Samples of 10 ,u were loaded in separate lanes on the TLC plates. Standards were run beside the samples on each plate for comparison. These plates were developed in 200 ml of the ethanol-ammonium acetate solvent for 3 h, dried, and then observed under UV light. For the production of [carbonyl-14C]NR, the lane for each sample was cut at intervals corresponding to the appropriate standard marker, and each section was placed in scintillation counting vials (Laboratory Product Sales, Rochester, N.Y.) with 5 ml of Filtron-X (National Diagnostics, Manville, N.J.) for measurement of radioactivity by liquid scintillation counting. 'H NMR. 'H NMR spectra were recorded at 500 MHz on a spectrometer (GN 500; General Electric Co., Schenectady, N.Y.). Samples of the nucleosides were lyophilized from 99.8% D20 twice and then dissolved in 100o D20 to a final concentration of 1 mg/ml. The sample volume was 0.5 ml. The results from the spectral analysis indicated that the structural conformations were consistent with published 'H NMR spectra obtained for NR and NMN (data not shown) (24) .
V-factor growth studies. H. influenzae was grown overnight at 37°C in BHI broth supplemented with 11.3 ,uM NAD and 15.8 ,uM hematin. A 1 in 3 dilution of the H. influenzae into fresh BHI broth was performed 2 h prior to the growth study. The cells were washed twice with 50 mM potassium phosphate buffer (pH 7.0) and suspended to a final concentration of 10' CFU/ml in BHI broth. The viable cell count of the initial inoculum was determined by titration on chocolate agar. Cells were diluted 1:10 into BHI broth supplemented with 15.8 ,uM hematin and the V-factor compound at concentrations from 3 to 3,000 ,uM. The final volume of each test sample was 1 ml. Reaction mixtures were incubated for 24 h at 37°C on a rotary shaker. Viable cell counts were determined in duplicate on chocolate agar. Growth was presented as the mean log number of CFU at 0 h and after 24 h of incubation.
In the inhibition studies, NAD, NMN, or NR was added to a final concentration of 3 p.M to a reaction mixture containing 15.8 p.M hematin, BHI broth, and the compound to be evaluated. The potential inhibitors were added at molar ratios of 1, 10, and 100 compared with the amount of V factor. Cells were added to a final concentration of 105 CFU/ml. Viable cell counts were determined on chocolate agar after 24 h of incubation. Results were presented as the mean log number of CFU at 0 h and after 24 h of incubation compared with the mean log number of CFU in the NAD, NMN, or NR growth controls.
Antimicrobial activity of 3-AmPR. Both Staphylococcus 
RESULTS
V-factor growth studies. Several NAD analogs were evaluated for their effectiveness as V-factor substitutes (Table  1) . Both the reduced and 3'-phosphorylated analogs of NAD functioned as well as NAD did. The NAD analogs with 3'-pyridine substitutions were found to support growth only when the modification consisted of either a thioamide or acetyl group. Carboxyl, aldehyde, amino, or iodo substitution resulted in compounds that were unable to support growth. Compounds in which only the adenine moiety was modified, which left the nicotinamide ring intact, supported the growth of H. influenzae.
NR analogs and modified nucleosides were evaluated ( Table 2 ). The compounds with 3'-pyridine modifications were found to correlate well with their respective dinucleotide counterparts, with the exception of the 3'-aldehydesubstituted compound. The aldehyde-substituted dinucleotide was found to be incapable of supporting growth, whereas the riboside supported growth approximately 1/10th as well as NR did. 3-AmPR was found to be the only 3'-substituted riboside that was unable to support the growth of H. influenzae. The NR analog with a xylofuranose ring substituted for the ribofuranose ring was found to support the growth of H. influenzae. The nucleosides from SloanKettering and the three nucleosides in which the glycopyridine linkage was a carbon atom (C nucleosides) did not function as V-factor substitutes.
Inhibition studies. Those NR analogs which did not support the growth of H. influenzae were evaluated for their ability to inhibit the growth of the organism by using 3 ,uM NR as the V factor (data not shown). b At the 10-2 dilution (the lowest measured), no growth occurred.
3-AmPR was found to be most effective when 3 ,M NAD served as the V factor (Fig. 2) . Antimicrobial activity of 3-AmPR. 3-AmPR had no effect on the growth of E. coli or S. aureus at concentrations of 30 and 300 ,M. Incubation of E. coli for 24 h in BHI broth 10' while the extracellular concentration of 3-AmPR and adenosine remained almost constant (Fig. 4) . Immediately after the addition of H. influenzae, it was found that a small fraction of the 3-AmPAD was metabolized to 3-AmPR and adenosine. After 4.25 h of incubation, it was inferred that the 3-AmPAD metabolites were internalized, with there being only a slight increase in the amount of extracellular 3-AmPR present. After 6 h of incubation, further metabolism and presumed internalization of the 3-AmPAD metabolites occurred, as indicated by the reduction of the peak representing 3-AmPAD.
Analysis of the extracellular broth from the incubation of 3-AmPAD with H. influenzae under uptake and nonuptake conditions indicated that 3-AmPAD was degraded to 3-AmPR in both cases. It was found that the uptake condition resulted in low levels of extracellular 3-ArmPR, whereas the nonuptake condition resulted in the accumulation of extracellular 3-AmPR (Fig. 5) . Indirect evidence for the internalization of 3-AmPR exists because of the accumulation of 3-AmPR that occurred under nonuptake conditions but that did not occur under uptake conditions. The 4-h samples also contained a peak, with a relative retention time of 3.0 min, which did not correspond with any of the degraded 3-AmPAD products. This peak may represent an undetermined product of cell metabolism. 
DISCUSSION
In this study we investigated the effect that NAD and NR analogs have on the NAD synthetic pathway of H. influenzae. The NAD analogs which contained an intact nicotinamide ring were found to support the growth of H. influenzae, including the analogs in which the adenine moiety was substituted with hypoxanthine, guanine, or 1,N6-ethenoadenine. It was found that substitutions on the adenine moiety of NAD reduced the -effectiveness with which these compounds supported growth. This phenomenon may have been due to the substrate specificity of the nucleotide pyrophosphatase, as determined in studies with the purified enzyme. NHD, NGD, and NED were found to be poor substrates in enzyme-catalyzed reactions (15) .
Some NAD analogs with 3'-pyridine alterations supported the growth of H. influenzae. The 3'-thioamide and 3'-acetyl substitutions resulted in growth, but they were less effective than NAD. Since both of these compounds are equivalent to NAD as substrates for the nucleotide pyrophosphatase (15), the reduction in growth was probably not due to the initial cleavage of the PP1 bond. These compounds supported the growth of H. influenzae; therefore, it is hypothesized that they were metabolized in the NAD synthetic pathway to ThioNAD or 3-AcPAD, which substitute for NAD in cellular oxidation-reduction reactions. Both compounds can serve as coenzymes in dehydrogenase reactions (2, 16) . ThioNAD serves as a coenzyme in horse liver alcohol dehydrogenase reactions more effectively than NAD does, but it appears to be less effective in all other tested dehydrogenase reactions (2). 3-AcPAD functions as a coenzyme in dehydrogenase reactions with yeast alcohol dehydrogenase, horse liver alcohol dehydrogenase, glutamic dehydrogenase, and triosephosphate dehydrogenase (16) . The effectiveness of 3-AcPAD, however, was found to be lower than that of NAD VOL. 34, 1990 on in each case. The lesser ability of ThioNAD and 3-AcPAD to serve as coenzymes in enzyme-catalyzed oxidation-reduction reactions may be the reason for their reduced efficacies as V-factor substitutes.
The NAD analogs which were unable to serve as V-factor substitutes included NAAD, 3-AmPAD, 3-PAAD, and 3-iodopyridine adenine dinucleotide (3-lodoPAD). Both NAAD and 3-AmPAD were previously found to be incapable of substituting for the V factor (5, 15) , although both are functional substrates for the nucleotide pyrophosphatase. Previous studies have shown that H. influenzae is incapable of aminating the carboxyl group of the nicotinic acid nucleotide (5) . NAAD has been investigated in dehydrogenase reactions, and it did not function as a coenzyme in either yeast alcohol dehydrogenase or glycerol dehydrogenase reactions (20) . 3-AmPAD has also been evaluated in dehydrogenase reactions and was found to be a competitive inhibitor in reactions catalyzed by seven NAD(P)-dependent enzymes (9, 26) . Neither 3-PAAD nor 3-IodoPAD was studied with the purified nucleotide pyrophosphatase; however, they have been evaluated in dehydrogenase reactions. 3-PAAD is known to inhibit glyceraldehyde 3-phosphate dehydrogenase covalently (13) . It has also been determined that 3-PAAD does not function as a coenzyme in triosephosphate dehydrogenase reactions (16) . Enzymatic studies with 3-IodoPAD determined that the compound is unable to serve as a coenzyme in pig heart malate, dogfish malate, and lactate dehydrogenase reactions (1) . This indicates that the ability of these NAD analogs to substitute as a V factor may depend upon their ability to serve as coenzymes in purified enzymatic dehydrogenase reactions.
The ability of the NR analogs to support growth seemed to correlate with their respective dinucleotide compounds. It was consistently found that NR supported growth with less effectiveness than that of NAD at equimolar concentrations (3, 15) . The initial cleavage of NAD that produces a source of AMP may help promote the growth of H. influenzae. Unpublished data from our laboratory, using NR along with AMP as growth factors, were found to be inconclusive. In a similar fashion, ThioNR and 3-AcPAD were found to be less effective V-factor substitutes than their respective dinucleotides were. The riboside derivative of 3-AmPAD was found to be incapable of supporting growth, which agreed well with the results obtained with 3-AmPAD. The riboside derivative of 3-PAAD was found to have activity as a V factor, whereas the dinucleotide did not. This suggests that the dinucleotide is not broken down to the riboside metabolite at the concentrations that we tested.
The NR analog in which the ribofuranose ring was exchanged for a xylofuranose ring was found to support the growth of H. influenzae. In this study, the nicotinamide xyloside was the only source of Nam. Since H. influenzae cannot synthesize NAD from Nam, the nicotinamide xyloside was probably incorporated into the NAD synthetic pathway. The [carbonyl-14C]NR uptake studies determined that the nicotinamide xyloside inhibited NR uptake when the concentration of nicotinamide xyloside was 1,000 times that of NR. The internalized nicotinamide xyloside could be synthesized into an NAD analog in which the pyridine ribofuranose ring was substituted by a xylofuranose ring. In order for growth to be maintained, this analog must be capable of functioning as a cofactor in the intracellular oxidation-reduction reactions.
The C nucleosides were found to be incapable of supporting growth. Based on the [carbonyl-14C]NR uptake studies, these compounds did not decrease the uptake of [carbonyl- 14C]NR by H. influenzae. This may be due, in part, to the difference in the geometry of a C nucleoside compared with that of an N nucleoside. The ability of the 3-aminopyridine compounds to inhibit the growth of H. influenzae led to investigation of the mechanism of inhibition. It was previously determined (15) that 3-AmPAD inhibits the growth of H. influenzae when NAD serves as the V factor. This could be due to a competition for the nucleotide pyrophosphatase or the metabolism, internalization, and resynthesis of 3-AmPAD into a nonfunctional cofactor that would competitively inhibit NAD in oxidation-reduction reactions. 3-AmPR inhibited the growth of H. influenzae when NR, NMN, or NAD was the V factor. Since 3-AmPR lacks a diesterified PPi group, it is unlikely to compete with NAD for this enzyme. The inhibits the uptake of NR and, therefore, may inhibit growth by preventing the internalization of NR and the subsequent synthesis of NAD. 3-AmPAD is readily metabolized to 3-AmPR in the presence of whole cells of H. influenzae. When 3-AmPAD was studied during uptake and nonuptake conditions, it was indirectly proven that 3-AmPR is internalized by H. influenzae. Since 3-AmPR did not inhibit the growth of E. coli or S. aureus, it is likely that 3-AmPR inhibits the growth of H. influenzae by interfering with its unusual NAD pathway. This could be accomplished if 3-AmPR were competing with NR or NMN for nicotinamide ribonucleoside kinase or nicotinamide mononucleotide adenyltransferase, respectively (Fig. 1) . 3-AmPR could also form 3-AmPAD and function to competitively inhibit the enzymes involved in the cellular oxidation-reduction reactions. It is possible that the 3-AmPR inhibits the growth of H. influenzae by an as yet undetermined mechanism.
Inhibition of the growth of H. influenzae by various NR analogs which interfere with the NAD pathway of the organism is feasible, as demonstrated by the 3-AmPR inhibition studies. There are several possible modes of inhibition by nucleoside analogs. An analog might compete with NR for the binding protein, thus blocking the uptake of NR. Modifications of the 5'-hydroxyl group of the ribofuranose ring could result in an analog that would be internalized but that would be incapable of phosphorylation by the nicotinamide ribonucleoside kinase. This would result in a competition with NR for this enzyme, depleting the NAD required for growth. Substitution on the pyridine ring of NR could result in an analog that is capable of uptake and subsequent synthesis of an NAD analog that is incapable of functioning as a cofactor. Analogs could inhibit the growth of H. influenzae by another mechanism. Further development of NR analogs may provide promising selective antimetabolites for Haemophilus species that require exogenous NAD and will enhance our understanding of this NAD pathway.
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